FDA Approves Tepotinib for Metastatic NSCLC
... (Tepmetko) for adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ...
... (Tepmetko) for adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ...
ROS1 fusion–positive non–small cell lung cancer (NSCLC). 1 This is the first U.S. Food and Drug Administration approval that includes ...
Pretreated Melanoma
Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC
Novel CAR T ...
... class HER2-targeting ADC for metastatic breast, gastric, and non-small cell lung cancer, Enhertu now becomes the first ADC with a tumour ...
... in the United States
Sexual Health Assessment in Women With Lung Cancer Study: Sexual Health Assessment in Women With Lung Cancer
EGFR </em ...
... first research results on CKD-703, a new drug candidate for non-small cell lung cancer, at the American Association for Cancer Research ...
FDA) has expanded the approval of fam-trastuzumab–deruxtecan-nxki (Enhertu; AstraZeneca and Daiichi Sankyo, Inc) to adults with ...
... additional treatment options.
Fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo), a HER2-directed antibody-drug ...
... -CRC02 trials.
Enhertu’s safety across all three studies was on par with the ADC’s previously-observed profile, AZ added.
Enhertu has ...
... 2022, the HER2-targeted ADC fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) became the first ADC to be approved by the for the ...